Cargando…

Long-term outcomes with pimavanserin for psychosis in clinical practice

INTRODUCTION: Pimavanserin is the only medication FDA-approved for the treatment of Parkinson disease (PD) psychosis (PDP), but reports of long-term, real-world clinical experience are lacking. METHODS: A retrospective chart review of all patients treated with pimavanserin was conducted at our large...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akbar, Umer, Friedman, Joseph H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036130/ https://www.ncbi.nlm.nih.gov/pubmed/35479873 http://dx.doi.org/10.1016/j.prdoa.2022.100143

Ejemplares similares

Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice
por: Dashtipour, Khashayar, et al.
Publicado: (2021)

Dementia-related psychosis and the potential role for pimavanserin
por: Cummings, Jeffery L., et al.
Publicado: (2022)

Pimavanserin: Potential Treatment For Dementia-Related Psychosis
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
por: Rissardo, Jamir Pitton, et al.
Publicado: (2022)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs, Brianna L, et al.
Publicado: (2017)

Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
por: Tampi, Rajesh R, et al.
Publicado: (2019)

Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
por: Srinivasan, Shilpa, et al.
Publicado: (2020)

Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review
por: Patel, Rikinkumar S, et al.
Publicado: (2019)

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications
por: Espay, Alberto J., et al.
Publicado: (2018)

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
por: Abler, Victor, et al.
Publicado: (2022)

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
por: Hacksell, Uli, et al.
Publicado: (2014)

Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature
por: Touma, Katie T. B., et al.
Publicado: (2018)

Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
por: Brown, Joshua D, et al.
Publicado: (2021)

Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review
por: Sellers, Jessie, et al.
Publicado: (2019)

HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2020)

Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series
por: Rothenberg, Kasia Gustaw, et al.
Publicado: (2023)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

Erratum to: HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2021)

Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions
por: Heim, Beatrice, et al.
Publicado: (2023)

Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis
por: Isaacson, Stuart H., et al.
Publicado: (2020)

Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis
por: Yunusa, Ismaeel, et al.
Publicado: (2020)

Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2022)

Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2021)

Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access
por: Livezey, Sabrina, et al.
Publicado: (2021)

Long-term outcomes in Amish patients diagnosed with propionic acidemia
por: Scott Schwoerer, Jessica, et al.
Publicado: (2018)

Psychosis as an adverse effect of antibiotics
por: Essali, Norah, et al.
Publicado: (2020)

Basic auditory processing and emotion recognition in individuals at clinical high risk for psychosis()
por: Kraus, Michael S., et al.
Publicado: (2021)

Later Age of Onset and Longer Duration of Untreated Psychosis are Associated with Poorer Outcome in Delusional Infestation
por: LEPPING, Peter, et al.
Publicado: (2020)

Penile transplantation: A long way to routine clinical practice
por: Li, Jinhong, et al.
Publicado: (2017)

Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
por: Ramachandran, Sharavan, et al.
Publicado: (2020)

Impact of specialty pharmacist integration on time to medication access for pimavanserin
por: Livezey, Sabrina, et al.
Publicado: (2019)

Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment
por: Ramachandran, Sharavan, et al.
Publicado: (2021)

Cardiopulmonary exercise testing variables as predictors of long-term outcome in thoracic sarcoidosis
por: Lopes, A.J., et al.
Publicado: (2012)

Short term clinical and echocardiography outcomes of pericardiectomy in constrictive pericarditis
por: Kumar, Madhur, et al.
Publicado: (2021)

Systemic infection drives urgent care needs and outcome in adults with long-term neurological conditions
por: Ramos, Ana Saldanha, et al.
Publicado: (2022)

Snus use and risk of schizophrenia and non-affective psychosis
por: Munafò, Marcus R., et al.
Publicado: (2016)

The protective effects of Pimavanserin against cerebral ischemia-induced brain injury
por: Li, Xiang, et al.
Publicado: (2021)

Adherence to long-term follow-up preventive practices in allogeneic hematopoietic cell transplantation survivors from North India
por: Khaire, Niranjan S., et al.
Publicado: (2022)

Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
por: Beck, Michael, et al.
Publicado: (2017)

Mini Mental State Examination (MMSE) in First Episode of Psychosis
por: Tatari, Faezeh, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lo16ji60lp4p2uqdbo3ehaeclc